EXCHANGE AGREEMENTExchange Agreement • November 9th, 2005 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • New York
This Exchange Agreement (this “Agreement”) is made as of the later of the dates set forth opposite the parties’ signatures (the “Agreement Date”) by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), and Alexandra Global Master Fund Ltd., a British Virgin Islands international business company (the “Investor”).
Radcliffe SPC, Ltd. — Class A Convertible Crossover Segregated Portfolio c/o RG Capital Management, L.P. Bala Cynwyd, PA 19004 Attention: Gerald Stahlecker, Managing Director Re: Exchange of 5% Convertible Subordinated Notes of Vertex Pharmaceuticals,...Letter Agreement • November 9th, 2005 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • New York
The purpose of this letter agreement (this “Agreement”) is to confirm the agreement of Vertex Pharmaceuticals Incorporated (“VRTX”) and Radcliffe SPC, Ltd. for and on behalf of its Class A Convertible Crossover Segregated Portfolio (the “Fund”) as follows:
Exchange AgreementExchange Agreement • November 9th, 2005 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • New York
This Exchange Agreement (this “Agreement”), dated as of September 8, 2005, is entered into between Vertex Pharmaceuticals Incorporated (the “Company”) and Quattro Fund, Ltd., Quattro Multi-Strategy Master Fund, LP, Partners Group Alternative Strategies PCC Limited, Red Delta Cell and Institutional Benchmark Series (Master Feeder) Limited in Respect of Electra Series (collectively, “Quattro”).
